The AKT1 knockout 769-P polyclonal cells consist of a CRISPR/Cas9-edited polyclonal population with targeted disruption of the AKT1 gene in the 769-P human renal cell carcinoma line. This format yields a heterogeneous pool of cells harboring gene edits across the population, which mitigates clonal bias and reflects the complexity of AKT1 loss in a tumor-like context. The polyclonal knockout model is suited for functional genomics studies, pathway analysis, and drug screening applications.
The 769-P cell line was originally established from a primary clear cell renal cell carcinoma (ccRCC) and grows as an adherent epithelial monolayer. These cells retain hallmark features of ccRCC, including dysregulation of hypoxia-inducible factor (HIF) and PI3K/AKT/mTOR signaling, making them a widely used model for renal cancer research. The 769-P background is particularly relevant for studying AKT1 function because ccRCC frequently exhibits PTEN inactivation or PI3K pathway hyperactivation, which drives AKT-dependent oncogenic signaling. Thus, AKT1 disruption in these cells provides a direct loss-of-function tool to dissect the kinase’s role in RCC biology.
AKT1 encodes a serine/threonine kinase central to the PI3K/AKT/mTOR pathway. Upon growth factor (EGF, IGF) stimulation through EGFR or IGF1R, PI3K generates PIP3, recruiting AKT1 to the membrane for phosphorylation by PDK1 (Thr308) and mTORC2 (Ser473). Active AKT1 phosphorylates substrates such as GSK3?? (inactivation), FOXO transcription factors (FOXO1/3/4; nuclear exclusion), TSC2 (inhibition), and BAD (pro-apoptotic suppression), thereby promoting cell survival, proliferation, and metabolism. PTEN opposes this pathway by dephosphorylating PIP3, while co-factors including PDPK1, HSP90, and PP2A modulate AKT1 activity. AKT1 dysregulation is linked to multiple cancers and metabolic disorders.
In clear cell renal cell carcinoma, AKT1 hyperactivity drives tumor progression by promoting proliferation, inhibiting apoptosis, and reprogramming metabolism toward aerobic glycolysis. The AKT1 knockout 769-P cells allow direct dissection of these AKT1-dependent phenotypes in a disease-relevant background. Comparing knockout and wild-type populations enables assessment of the kinase’s contribution to ccRCC cell growth, survival under nutrient stress, and sensitivity to PI3K or mTOR inhibitors. The model also facilitates studies of AKT1 crosstalk with insulin signaling and mTORC1/2, and serves as a platform for validating AKT1 as a therapeutic target in renal cancer.
Typical experimental applications include signal transduction profiling via western blotting for total and phospho-AKT1, as well as downstream effectors like phospho-GSK3?? and phospho-FOXO. Cell proliferation, apoptosis (Annexin V staining), and cell cycle analyses are readily performed to evaluate growth and survival phenotypes. Metabolic reprogramming can be assessed with glucose uptake assays, while cell migration and invasion are measured using transwell chambers. Phospho-kinase arrays and drug sensitivity screens with PI3K/mTOR pathway inhibitors (e.g., everolimus, GDC-0941) further expand the utility of this model in cancer biology and drug discovery. For additional product details, protocols, or bulk pricing, please contact Ascent Research.
